Browsing Tag
AbbVie
63 posts
Zydus Lifesciences, Daewoong Pharmaceutical forge US market alliance for Leuprolide Acetate
Zydus Worldwide DMCC, a wholly-owned subsidiary of Zydus Lifesciences Ltd., and South Korea’s Daewoong Pharmaceutical Co., Ltd. have…
AbbVie to acquire Cerevel Therapeutics for $8.7bn to expand neuroscience research
AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) have announced a definitive agreement in which AbbVie will…
AbbVie to acquire ImmunoGen for $10.1bn to expand oncology portfolio
AbbVie Inc. and ImmunoGen Inc. have entered into a definitive agreement, marking a significant move in the pharmaceutical…
ABBV-RGX-314 : REGENXBIO reports positive Phase 2 data on diabetic retinopathy gene therapy candidate
REGENXBIO Inc. has disclosed new findings from its Phase II ALTITUDE trial, focusing on ABBV-RGX-314 as a gene…
AbbVie, Calibr to drive preclinical and clinical advancements in expanded partnership
AbbVie and Scripps Research institute’s division Calibr have announced a broadened strategic collaboration targeted at developing preclinical and…
Caplin Point to tap into $35m market after FDA approval for NIMBEX generic
Caplin Steriles, a subsidiary of India’s Caplin Point Laboratories, has obtained final approval from the US Food and…
Genmab gets EPKINLY FDA approval for diffuse large B-cell lymphoma
Danish biotech company Genmab has secured accelerated approval for EPKINLY (epcoritamab-bysp) from the US Food and Drug Administration…
AbbVie bags RINVOQ FDA approval for nr-axSpA in adults
RINVOQ FDA approval for nr-axSpA : AbbVie has bagged approval for its selective JAK inhibitor RINVOQ (upadacitinib 15…
AbbVie acquires UK biotech company DJS Antibodies for $255m
AbbVie has acquired DJS Antibodies, a privately-held UK-based biotech company, in an all-cash transaction valued at approximately $255…
Harpoon Therapeutics gets FDA fast track status for HPN217 in RRMM
Harpoon Therapeutics has bagged fast track designation for HPN217 from the US Food and Drug Administration (FDA) for…